Convelo Therapeutics is developing two experimental oral treatments to promote myelin repair in multiple sclerosis (MS) and both have shown promise in preclinical models.
The company is in the final stages of safety studies in large animals. Once those studies are done, it plans to start studies that support regulatory applications to move the treatments toward clinical trials, according to Brad Lang, Convelo’s vice president of research.
https://mtrb.org/the-future-of-stem-cell-therapy-for-ms-multiple-sclerosis-treatment/
No comments :
Post a Comment